Positive Data, Pipeline Improvements & Market Expansion - Research Report on Abbott Laboratories, Stryker Corporation, St. Jude

 Positive Data, Pipeline Improvements & Market Expansion - Research Report on
  Abbott Laboratories, Stryker Corporation, St. Jude Medical, Cardiovascular
                          Systems and MAKO Surgical

PR Newswire

NEW YORK, March 13, 2013

NEW YORK, March 13, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Abbott
Laboratories (NYSE: ABT), Stryker Corporation (NYSE: SYK), St. Jude Medical,
Inc. (NYSE: STJ), Cardiovascular Systems Inc (NASDAQ: CSII) and MAKO Surgical
Corp. (NASDAQ: MAKO). Today's readers may access these reports free of charge
- including full price targets, industry analysis and analyst ratings - via
the links below.

Abbott Laboratories Research Report

Abbott Laboratories has released new data indicating that Abott's Absorb
Bioresorbable Vascular helps improve blood vessel movement in patients with
coronary heart disease (CAD). Absorb is the first of its kind device that
works by opening clogged vessels and restoring blood flow. Unlike metallic
stents, Absorb dissolve over time, potentially allowing natural blood flow to
return. Absorb is already commercially available in Europe and other
international market, but is still an investigational device in the United
States. Separately, Abbott announced data from the EVEREST II study, showing
that Abbott's MitraClip System may help treat patients who are not allowed to
go through mitral valve surgery due to risk of mortality. With these products,
Abbott is well-positioned to capitalize on the United States' vascular market.
The Full Research Report on Abbott Laboratories - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.investors-alliance.com/r/full_research_report/9cb0_ABT]

--

Stryker Corporation Research Report

Stryker recently completed its acquisition of Trauson Holdings Company
Limited, a manufacturer of trauma-related products in China. This acquisition
is a critical step in helping Stryker broadens its presence in the region,
though the financial benefits of this acquisition is not expected to impact
Stryker's earnings for 2013. Due to this acquisition, Goldman Sachs reiterated
its Buy rating on Stryker Corporation and promptly increased its price target
from $71 to $72. Goldman Sachs notes that this acquisition could be accretive
for Stryker in the long-term, especially if Stryker "proves successful at
leveraging Trauson's existing channels in China to sell a broader product
range." Stryker's deepened presence in emerging markets helps position it for
future growth. The Full Research Report on Stryker Corporation - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/8335_SYK]

--

St. Jude Medical, Inc. Research Report

St. Jude Medical makes its way to Japan by launching its ILUMIEN OPTIS System
in the region. The product is used to help physicians make personalized
stenting decisions based on each patient's unique anatomy and disease state.
According to William Phillips, president of St. Jude Medical Japan, the
company is excited about expanding its reach of the ILUMIEN OPTIS in Japan, a
world leader in imaging technology. In Japan, around 245,000 Percutaneous
Coronary Intervention (PCI) procedures are performed to treat cardiovascular
disease, and 80 percent are said to use the technology, showing the potential
market for ILUMIEN OPTIS. Aside from this, St. Jude Medical's AMPLATZER
Cardiac Plug, a product for the prevention of stroke, is said to be on track
with its development, showing continued strength in the company's atrial
fibrillation business. These latest developments are in line with the
company's commitment to deliver strong EPS growth without sacrificing
investment for its pipeline. The Full Research Report on St. Jude Medical,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/d3fb_STJ]

--

Cardiovascular Systems Inc Research Report

Cardiovascular Systems made headlines after the company presented results from
its ORBIT II study of severely calcified coronary lesions. The results showed
that CSI's orbital atherectomy technology may be a viable treatment option for
patients with severe calcified lesions. The results showed study endpoints
were met by a significant margin. These results make the prospects of the
company's coronary business seem brighter, helping it move forward towards its
goal of filing the product for FDA approval. The company believes that the
market opportunity for this technology is estimated to exceed $1.5 billion
annually in the US alone. Shares of Cardiovascular Systems jumped 16.55
percent following the release of these results. The Full Research Report on
Cardiovascular Systems Inc - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/8bf1_CSII]

--

MAKO Surgical Corp. Research Report

MAKO has been steadily gaining after the robotic arm and orthopedic implants
manufacturer reported impressive fourth quarter and full year 2012 results.
Its revenue for the year totaled at $102.7 million, showing an increase of 22
percent over 2011. This increase was due to stronger sales of RIO systems and
higher MAKOplasty procedure volumes. At present, the company is currently
training physicians to perform its procedures to increase the volume of
MAKOplasty procedures, drive sales of its RIO systems, and increase
profitability. The Full Research Report on MAKO Surgical Corp. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/1687_MAKO]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@Investors-Alliance.com
Main: +1-480-745-7826

SOURCE Investors-Alliance
 
Press spacebar to pause and continue. Press esc to stop.